A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer-Reference-Cited by-同舟云学术

A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Published:2020-07-21 Issue:20 Volume:26 Page:5338-5347
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Aggarwal Rahul R.,Schweizer Michael T.,Nanus David M.,Pantuck Allan J.,Heath Elisabeth I.^ORCID,Campeau Eric^ORCID,Attwell Sarah,Norek Karen,Snyder Margo^ORCID,Bauman Lisa,Lakhotia Sanjay,Feng Felix Y.,Small Eric J.,Abida Wassim,Alumkal Joshi J.^ORCID

Funder

Zenith Epigenetics

Department of Defense Prostate Cancer Research Program

NIH NCI Cancer Center Support grant

Prostate Cancer SPORE

Prostate Cancer Foundation

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting;The Prostate;2024-04-29

2. Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review);Oncology Reports;2024-04-12

3. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications;Nature Reviews Cancer;2024-04-08

4. Co‐targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor‐null prostate cancer;The Journal of Pathology;2024-04-05

5. Transcription Factors in Prostate Cancer: Insights for Disease Development and Diagnostic and Therapeutic Approaches;Genes;2024-04-02